Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06307080 | Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis | recruiting | N/A | 12 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06149546 | Exploring the Impact of a Multi-modal Nutritional Intervention in Patients Undergoing Chemotherapy for Pancreatic Cancer (FEED Trial)(FEED) | recruiting | N/A | 70 | Cancer Trials IrelandNETWORK |
| 1 |
| Jul 8, 2025 |
| clinicaltrials |
| NCT07054879 | CtDNA-guided Maintenance Therapy in Pancreatic Cancer | recruiting | — | 70 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT06585072 | Pancreatic Cancer and Diabetes Mellitus | recruiting | — | 150 | Shanghai Changzheng HospitalOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT07045571 | MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer | recruiting | — | 1,000 | Yingbin Liu, MD, PhD, FACSOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT05451043 | Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) | recruiting | Phase 2 | 62 | AHS Cancer Control AlbertaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07035587 | Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques | recruiting | — | 1,200 | Yonsei UniversityOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07030348 | Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study | recruiting | — | 263 | Do Hyun ParkOTHER | 2 | Jun 22, 2025 | clinicaltrials |
| NCT06135896 | Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers(Dulastin) | recruiting | Phase 2 | 98 | National Cancer Center, KoreaOTHER_GOV | 1 | Jun 18, 2025 | clinicaltrials |
| NCT02843945 | Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source | recruiting | Phase 1 / Phase 2 | 80 | CivaTech OncologyINDUSTRY | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07007832 | Bile Omics for Diagnosing Indeterminate Biliary Strictures | recruiting | — | 260 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT07015580 | The Characteristics of Oral Microbiota in Chronic Pancreatitis and Autoimmune Pancreatitis | recruiting | — | 360 | Ruijin HospitalOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 150 | Cancer Research UKOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06596915 | Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 167 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06914349 | Antecolic Versus Retrocolic Gastrojejunostomy During Whipple's Procedure | recruiting | N/A | 76 | University of ThessalyOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT05241249 | Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma | recruiting | Phase 2 | 37 | Susan E. BatesOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT05740956 | A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 318 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06816823 | CAR-NK Cells (CL-NK-001) in Pancreatic Cancer | recruiting | Phase 1 | 30 | Changhai HospitalOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06164769 | Enucleation of Pancreatic Tumor by Blocking Abdominal Trunk and Superior Mesenteric Artery | recruiting | N/A | 30 | Zhejiang UniversityOTHER | 1 | Jun 2, 2025 | clinicaltrials |
| NCT06564571 | Artificial Intelligence in Endoscopic Ultrasound | recruiting | — | 310 | Orlando Health, Inc.OTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06944106 | A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT04084496 | mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients | recruiting | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06277531 | Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE)(ECCBILE) | recruiting | — | 99 | Peking University Third HospitalOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06538857 | CEB-01 in Locally Resectable Pancreatic Cancer | recruiting | Phase 2 | 39 | CEBIOTEXINDUSTRY | 1 | May 23, 2025 | clinicaltrials |
| NCT06577532 | Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors | recruiting | Early Phase 1 | 56 | Ruijin HospitalOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT06515587 | Clinical Study of Lewis Antigen Assay Combined With CA19-9 Assay to Assess Prognosis in Patients With Pancreatic Cancer | recruiting | N/A | 40 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06532617 | Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer | recruiting | Phase 2 | 30 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT04276857 | Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer(SMART) | recruiting | N/A | 27 | University of SaskatchewanOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06332274 | tislelizUMaB in canceR Patients With molEcuLar residuaL Disease(UMBRELLA) | recruiting | Phase 3 | 717 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06962267 | A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type) | recruiting | Phase 2 | 50 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT04037007 | Efficacy of Fistulotomy for Biliary Cannulation | recruiting | N/A | 320 | Coordinación de Investigación en Salud, MexicoOTHER_GOV | 1 | May 1, 2025 | clinicaltrials |
| NCT04503265 | A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 122 | AtlasMedx, IncorporatedINDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT06121622 | Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours(3DPanNET) | recruiting | — | 70 | IRCCS San RaffaeleOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT05827796 | IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 70 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06945978 | Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer (mirPANC 2)(mirPANC 2) | recruiting | — | 60 | Benedito Mauro RossiOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06944587 | A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer(NORPACT-3) | recruiting | — | 400 | Oslo University HospitalOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06822413 | Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis | recruiting | — | 600 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT05518643 | Compliance With ERAS Protocol in Pancreatic Surgery, Stress Response and Outcomes | recruiting | — | 120 | University of ThessalyOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06937112 | 18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis | recruiting | — | 20 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06760364 | A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer(CHAMPION) | recruiting | Phase 1 | 21 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06914674 | Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas(SPTP) | recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT05298722 | Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial)(PeRFormanCe) | recruiting | N/A | 45 | University Hospital, GhentOTHER | 2 | Apr 2, 2025 | clinicaltrials |
| NCT05776524 | Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer | recruiting | Phase 2 | 46 | THERABIONIC INC.OTHER | 1 | Mar 25, 2025 | clinicaltrials |
| NCT05653453 | Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer | recruiting | Phase 3 | 512 | Jiangsu Healthy Life Innovation Medical Technology Co., LtdINDUSTRY | 1 | Mar 24, 2025 | clinicaltrials |
| NCT06638866 | AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort(AI-PANC) | recruiting | — | 5,000 | Changhai HospitalOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06883539 | A Phase I Study of LXP1788 Injection with Advanced Solid Tumors. | recruiting | Phase 1 | 24 | LaunXP Biomedical Co., Ltd.INDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06757244 | DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer(DOVIPA) | recruiting | Phase 2 | 35 | Hopital FochOTHER | 1 | Mar 18, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jul 9, 2025source: clinicaltrials